Bfsg LLC Has $2.44 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Bfsg LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 1.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,959 shares of the company’s stock after acquiring an additional 42 shares during the period. Bfsg LLC’s holdings in Eli Lilly and Company were worth $2,444,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter worth $43,000. FPC Investment Advisory Inc. lifted its position in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter worth $48,000. Highline Wealth Partners LLC lifted its position in Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock worth $57,000 after purchasing an additional 24 shares during the period. Finally, Capital A Wealth Management LLC bought a new position in Eli Lilly and Company in the fourth quarter worth $63,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Finally, Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $807.62 on Tuesday. The firm has a market capitalization of $765.41 billion, a P/E ratio of 68.97, a PEG ratio of 1.40 and a beta of 0.40. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The business has a 50-day moving average of $777.10 and a 200-day moving average of $801.77. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the firm posted $2.58 earnings per share. Eli Lilly and Company’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a $1.50 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.